FDA Accepts Supplement Application for Neulasta (Pegfilgrastim)
The FDA has accepted a supplemental application for Neulasta (pegfilgrastim) from Amgen.
Asset / Drug
Drug and asset intelligence for Neulasta with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.